Skip to content
HomeLatest newsInnovationMeet 3 men who’ve been on the front lines of HIV treatments for decades
Left to right: Joss J. De Wet, M.D., Johnson & Johnson's Brian Woodfall, M.D., and artist Tiko Kerr
Left to right: Joss J. De Wet, M.D., Johnson & Johnson’s Brian Woodfall, M.D., and artist Tiko Kerr Andy Meyers at M3 Creative

Meet 3 men who’ve been on the front lines of HIV treatments for decades

Johnson & Johnson’s Brian Woodfall, M.D., was working at a Vancouver clinic in the mid-1990s. That’s where he met Tiko Kerr, who became one of the first patients to take the company’s HIV medicines—and has thrived to this day. For National AIDS Awareness Month, watch as Kerr, Dr. Woodfall and fellow researcher Joss J. De Wet, M.D., reflect on how those treatments have saved lives and continue to evolve, in this moving video.

Left to right: Joss J. De Wet, M.D., Johnson & Johnson’s Brian Woodfall, M.D., and artist Tiko Kerr Andy Meyers at M3 Creative
hqdefault.jpg

We’re committed to helping lead the fight against HIV/AIDS

Read about the many ways Johnson & Johnson is working to #makeHIVhistory.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.